We are live on ! Find out more
ECYT

Endocyte, Inc. Common Stock
ECYT

Delisted

ECYT was delisted on the 20th of December, 2018.

Back to rankings

75 hedge funds and large institutions have $18.4M invested in Endocyte, Inc. Common Stock in 2017 Q2 according to their latest regulatory filings, with 15 funds opening new positions, 16 increasing their positions, 28 reducing their positions, and 22 closing their positions.

New
Increased
Maintained
Reduced
Closed

9% less funds holding

Funds holding: 82 → 75 (-7)

32% less first-time investments, than exits

New positions opened: 15 | Existing positions closed: 22

43% less repeat investments, than reductions

Existing positions increased: 16 | Existing positions reduced: 28

49% less capital invested

Capital invested by funds: $35.8M → $18.4M (-$17.4M)

68% less call options, than puts

Call options by funds: $147K | Put options by funds: $457K

Holders
75
Holders Change
-7
Holders Change %
-8.54%
% of All Funds
1.87%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
15
Increased
16
Reduced
28
Closed
22
Calls
$147K
Puts
$457K
Net Calls
-$310K
Net Calls Change
-$564K

Top Buyers

Rank Fund Capital Flow
1
Morgan Stanley
Morgan Stanley
New York
+$950K
2
Millennium Management
Millennium Management
New York
+$927K
3
Goldman Sachs
Goldman Sachs
New York
+$846K
4
AFM
Anson Funds Management
Texas
+$411K
5
PAM
Panagora Asset Management
Massachusetts
+$390K

Top Sellers

Rank Fund Capital Flow
1
BlackRock
BlackRock
New York
-$3.55M
2
State Street
State Street
Massachusetts
-$1.34M
3
JP Morgan Chase
JP Morgan Chase
New York
-$791K
4
Northern Trust
Northern Trust
Illinois
-$681K
5
Vanguard Group
Vanguard Group
Pennsylvania
-$650K
Name Holding Trade Value Shares
Change 		Change in
Stake
New York State Common Retirement Fund
76
New York State Common Retirement Fund
New York
– -$187K -72,923 Closed
TA
77
Teachers Advisors
New York
– -$167K -65,119 Closed
Stifel Financial
78
Stifel Financial
Missouri
– -$112K -45,353 Closed
State Board of Administration of Florida Retirement System
79
State Board of Administration of Florida Retirement System
Florida
– -$111K -43,302 Closed
RhumbLine Advisers
80
RhumbLine Advisers
Massachusetts
– -$111K -43,259 Closed
Two Sigma Investments
81
Two Sigma Investments
New York
– -$81K -31,641 Closed
NCCM
82
Nine Chapters Capital Management
New Jersey
– -$60K -23,500 Closed
AIG
83
American International Group
New York
– -$60K -23,410 Closed
VOYA Investment Management
84
VOYA Investment Management
Georgia
– -$60K -23,200 Closed
CG
85
Cutler Group
California
– -$47.8K -22,237 -99%
WS
86
Wedbush Securities
California
– -$56K -21,884 Closed
AllianceBernstein
87
AllianceBernstein
Tennessee
– -$50K -19,500 Closed
RJA
88
Raymond James & Associates
Florida
– -$33K -12,900 Closed
Legal & General Group
89
Legal & General Group
United Kingdom
– -$23K -9,583 Closed
AIM
90
Acrospire Investment Management
Illinois
– -$15K -5,735 Closed
AIP
91
Ameritas Investment Partners
Nebraska
– -$7K -2,665 Closed
Bank of Montreal
92
Bank of Montreal
Ontario, Canada
– -$5K -2,002 Closed
CPIG
93
Chicago Partners Investment Group
Illinois
– -$3K -1,000 Closed
SEI Investments
94
SEI Investments
Pennsylvania
– -$1K -427 Closed
Citigroup
95
Citigroup
New York
– -$1K -304 Closed
VWA
96
V Wealth Advisors
Kansas
– +$215 +100 New
1 2 3
4

ECYT Hedge Fund Activity: Q2 2017 in Review

75 of the 4,011 institutional investors tracked by Wall St. Rank reported a position in Endocyte, Inc. Common Stock (ECYT) for Q2 2017, worth a combined $18.4M — down 49% from $35.8M a quarter earlier.

Sellers outnumbered buyers: 22 funds closed out of ECYT and 15 opened new positions — a net loss of 7 holders — while 28 trimmed existing stakes and 16 added.

The largest buyer was Morgan Stanley, adding an estimated $950K. The largest seller was BlackRock, cutting an estimated $3.55M.

  • 75 institutional investors held Endocyte, Inc. Common Stock (ECYT) as of Q2 2017, down from 82 in Q1 2017.
  • Funds reported $18.4M of Endocyte, Inc. Common Stock stock for Q2 2017, down 49% quarter-over-quarter.
  • 15 funds opened new Endocyte, Inc. Common Stock positions in Q2 2017 and 22 closed out, a net change of -7 holders.
  • The largest Endocyte, Inc. Common Stock buyer in Q2 2017 was Morgan Stanley, an estimated $950K added.
  • The largest Endocyte, Inc. Common Stock seller in Q2 2017 was BlackRock, an estimated $3.55M sold.

Based on aggregated 13F filings for Q2 2017.